# A Trial of AK104 or AK112 in Combination With Axitinib in Patients With Metastatic Mucosal Melanoma

> **NCT06424626** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Peking University Cancer Hospital & Institute** · enrollment: 60 (estimated)

## Conditions studied

- Melanoma
- Mucosal Melanoma
- Metastatic Melanoma

## Interventions

- **DRUG:** AK104+Axitinib
- **DRUG:** AK112+Axitinib

## Key facts

- **NCT ID:** NCT06424626
- **Lead sponsor:** Peking University Cancer Hospital & Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-05-21
- **Primary completion:** 2025-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2024-05-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06424626

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06424626, "A Trial of AK104 or AK112 in Combination With Axitinib in Patients With Metastatic Mucosal Melanoma". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT06424626. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*